Clinical Trial Update: Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS [Phase 2]

View source ↗

Summary

Phase 2 trial of tipifarnib in advanced squamous non-small cell lung cancer with HRAS mutations has been terminated; results were posted in March 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Spanish Lung Cancer Group | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-03-29